公开(公告)号：US20150320871A1

公开(公告)日：2015-11-12

申请号：US14808668

申请日：2015-07-24

Applicant: Indiana University Research and Technology Corporation

Inventor： Richard D. DiMARCHI ,  Bin YANG ,  Brian FINAN

IPC: A61K47/48 ,  C07K14/605

CPC classification number: C07K14/721 ,  A61K38/26 ,  A61K47/55 ,  A61K47/554 ,  A61K47/64 ,  C07K14/605 ,  C07K14/72

Abstract: Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.

Abstract translation: 本文提供了与能够作用于核激素受体的NHR配体缀合的胰高血糖素超家族肽。 本文还提供了本发明的缀合物的药物组合物和试剂盒。 本文还提供了治疗疾病，例如代谢紊乱（例如糖尿病和肥胖症）的方法，其包括施用本发明的缀合物。

公开(公告)号：US20190388510A1

公开(公告)日：2019-12-26

申请号：US16302795

申请日：2017-05-26

Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： Richard D. DIMARCHI ,  Brian FINAN ,  Bin YANG ,  Zhimeng ZHU

IPC: A61K38/26 ,  A61K47/55 ,  A61P3/06 ,  A61P3/04 ,  A61P9/10 ,  A61K31/198

Abstract: Provided herein are glucagon agonist peptides conjugated with thyroid hormone receptor ligands that are capable of acting at the thyroid hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes, obesity, metabolic syndrome and chronic cardiovascular disease, comprising administering the conjugates of the invention.

公开(公告)号：US20190290772A1

公开(公告)日：2019-09-26

申请号：US16302846

申请日：2017-05-26

Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： Richard D. DIMARCHI ,  Brian FINAN ,  Bin YANG ,  Zhimeng ZHU

IPC: A61K47/55 ,  A61K47/54 ,  A61K47/65 ,  A61K47/64 ,  A61K31/197 ,  A61K38/26

Abstract: Provided herein are GLP-1 agonist peptides conjugated with thyroid hormone receptor ligands that are capable of acting at the thyroid hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes, obesity, metabolic syndrome and chronic cardiovascular disease, comprising administering the conjugates of the invention.